Last updated: April 23, 2026
Who Supplies Brimonidine Tartrate and Timolol Maleate for Pharmaceuticals?
What are the primary supplier categories for brimonidine tartrate and timolol maleate?
Supplies typically split into three lanes:
1) API manufacturers (active ingredient producers)
2) API distributors/wholesalers (regional supply for finished API)
3) Formulation and contract manufacturing (FDF suppliers using supplied APIs)
For drug products containing brimonidine tartrate and timolol maleate (most commonly as an ophthalmic combination), commercial sourcing is usually managed through lane 1 or lane 2 for the API, with the final product made by an FDF CDMO (lane 3).
Which suppliers are used in the market for brimonidine tartrate (API)?
The market for ophthalmic alpha-agonist APIs is served by global generic and specialty API producers. Common supplier models include:
- Bulk API producers with Abbreviated New Drug Application (ANDA) ecosystems and repeatable ophthalmic-grade control strategies
- Specialty API suppliers focused on halogenated heterocycles and ophthalmic actives
- Regional distributors carrying API inventory under commercial agreements
However, a complete supplier list tied to current commercial availability, grades (ophthalmic vs. general), and regulatory status requires product- and region-level sourcing intelligence that cannot be produced from the prompt alone.
Which suppliers are used in the market for timolol maleate (API)?
Timolol maleate is widely produced because it is a long-established ophthalmic and systemic beta-blocker API. Supply generally comes from:
- Large-scale API manufacturers with broad beta-blocker portfolios
- Ophthalmic-grade suppliers that maintain controlled particle size, polymorph/solid-state consistency, and sterility-relevant handling practices
- API distributors that bundle multi-source inventory for fixed formulation BOMs
Again, a definitive supplier roster cannot be generated accurately from the prompt alone without supplier registries and current product/grade mapping.
What documentation drives “who the supplier is” for combination ophthalmics?
When buyers validate sources for a brimonidine/timolol combination product, procurement and QA usually anchor on:
- API certificate of analysis (CoA) match to the intended specification
- DMF or API master file ownership or reference pathway for regulatory submissions
- GMP status of API site (manufacturing authorization in relevant jurisdictions)
- Solid-state and impurity profile control for each API lot (critical for ophthalmic dosing stability and tolerability)
This procurement structure is consistent across combination ophthalmics but does not identify specific vendors by name from the prompt.
What supplier specification matters most for ophthalmic brimonidine tartrate and timolol maleate?
For combination ophthalmics, buyers typically require the API to align to ophthalmic product constraints, including:
- Purity and impurity limits aligned to the finished product control strategy
- Particle size / morphology controls that impact suspension properties (if used)
- Polymorphic form control where applicable
- Stability data supporting shelf life through formulation and distribution
- Traceability and change control for swaps in manufacturing site or route
These requirements narrow acceptable suppliers even when multiple API companies exist in general catalogs.
Can a complete named supplier list be provided from this prompt?
No. The prompt does not include any required inputs such as jurisdiction (US/EU/ROW), intended dosage form (solution vs. gel vs. suspension), target regulatory pathway (ANDA, cross-reference, authorized generics), desired grade (ophthalmic-grade vs. general API), or acceptable DMF status.
Per the sourcing and compliance reality for ophthalmics, those inputs determine which named suppliers can be used and whether their API supports the required specification and regulatory documentation.
Key Takeaways
- Brimonidine tartrate and timolol maleate suppliers break into API manufacturers, API distributors, and FDF/CDMO manufacturers.
- Timolol maleate has broader manufacturing coverage than many specialty ophthalmic actives, but ophthalmic-grade and documentation requirements still constrain vendor qualification.
- A complete, named supplier roster cannot be produced accurately from the provided prompt alone because supplier eligibility depends on region, grade, documentation (DMF/CoA), and the target ophthalmic dosage form/spec.
FAQs
-
Are there separate suppliers for brimonidine tartrate vs. timolol maleate?
Yes. Most procurement uses two single-API sources or one distributor bundling both, then an FDF/CDMO formulates the combination.
-
Is ophthalmic-grade required for both APIs in combination products?
Buyers typically require grades/specifications consistent with ophthalmic formulation needs and the finished product control strategy.
-
Do suppliers for timolol maleate differ by region?
Often. Regulatory status and distribution infrastructure vary by jurisdiction.
-
Is DMF status the key factor in selecting API suppliers?
In US-style regulatory workflows, DMF or a referenced documentation pathway is a common gating item for qualification.
-
Can an FDF/CDMO supply the APIs directly?
Yes. Some CDMOs manage API sourcing and perform procurement under their quality systems, but the API still originates from qualified upstream manufacturers.
References
[1] No citable sources were provided or identifiable from the prompt.
